ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage. - Wikidata - awgldk - TriplyDB

ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage.

ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage.

http://www.wikidata.org/entity/Q33349055

about

Binding of ADAMTS13 to von Willebrand factor Inhibition of ADAMTS-7 and ADAMTS-12 degradation of cartilage oligomeric matrix protein by alpha-2-macroglobulin ADAMTS-12 associates with and degrades cartilage oligomeric matrix protein Pathophysiology of thrombotic thrombocytopenic purpura Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura Current concepts in thrombotic thrombocytopenic purpura Pathogenesis of thrombotic microangiopathies ADAMTS proteinases: a multi-domain, multi-functional family with roles in extracellular matrix turnover and arthritis.ADAM and ADAMTS Family Proteins and Snake Venom Metalloproteinases: A Structural Overview The Function and Roles of ADAMTS-7 in Inflammatory Diseases Proteolytic processing of von Willebrand factor by adamts13 and leukocyte proteases Metalloproteases Affecting Blood Coagulation, Fibrinolysis and Platelet Aggregation from Snake Venoms: Definition and Nomenclature of Interaction Sites Cleavage of ultra-large von Willebrand factor by ADAMTS-13 under flow conditions The von Willebrand factor-cleaving protease (ADAMTS-13) and the diagnosis of thrombotic thrombocytopenic purpura (TTP)Mapping of the disease locus and identification of ADAMTS10 as a candidate gene in a canine model of primary open angle glaucoma Identification of strain-specific variants of mouse Adamts13 gene encoding von Willebrand factor-cleaving protease Essential domains of a disintegrin and metalloprotease with thrombospondin type 1 repeats-13 metalloprotease required for modulation of arterial thrombosis.Carboxyl terminus of ADAMTS13 directly inhibits platelet aggregation and ultra large von Willebrand factor string formation under flow in a free-thiol-dependent manner.Further characterization of ADAMTS-13 inactivation by thrombin.Ten candidate ADAMTS13 mutations in six French families with congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome).von Willebrand factor: two sides of a coin.Enzymatically active ADAMTS13 variants are not inhibited by anti-ADAMTS13 autoantibodies: a novel therapeutic strategy?Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays.Systemic antithrombotic effects of ADAMTS13.Insights into von Willebrand factor proteolysis: clinical implications.Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo.ADAMTS13 and microvascular thrombosis An IAP retrotransposon in the mouse ADAMTS13 gene creates ADAMTS13 variant proteins that are less effective in cleaving von Willebrand factor multimers.Thrombotic thrombocytopenic purpura: a thrombotic disorder caused by ADAMTS13 deficiency The kidney in thrombotic thrombocytopenic purpura.Correction of ADAMTS13 deficiency by in utero gene transfer of lentiviral vector encoding ADAMTS13 genes.The distal carboxyl-terminal domains of ADAMTS13 are required for regulation of in vivo thrombus formation.An autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWF Humoral immune response to ADAMTS13 in acquired thrombotic thrombocytopenic purpura.[ADAMTS13, von Willebrand factor specific cleaving protease].Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura.Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura.Crystal structure and enzymatic activity of an ADAMTS-13 mutant with the East Asian-specific P475S polymorphism.Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura.ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 1. Structural and functional characterization in vitro

P2860

Q24299876-3344E703-A0DB-4C98-B6DE-1E6EC42BCF3C Q24313406-60AFA938-F9DF-4657-AAC5-7BD6C4E4BF50 Q24317122-A3ACAC37-6B7B-44DD-BA5B-6D2A79340D36 Q24614117-32F429EA-FDA8-4C58-AE2A-1447893B9DBA Q24651320-DDB2AD15-35B6-42D2-899E-025C3379AE96 Q24656680-2EB3F901-9935-4406-9F01-5078C807DA14 Q24658043-A1B0EF70-F647-4D81-827B-14C05EE81E26 Q24810478-C57D4193-DADA-419D-B9CA-47403979C88B Q26747656-B0792C09-532C-4E7E-8D0B-C486B41CEE80 Q26773190-07216800-858B-4548-8582-82421F3761C7 Q26827966-8393DA0D-6B2C-44A2-A9CE-02E2FFCE43F9 Q28075348-5383A6FA-E8C3-4167-A042-250EBC9FF6A0 Q28267403-2C64AD8F-AEC3-40D8-9D9E-E6A39085568B Q28305837-F603CDAA-3DA4-42BA-92D6-EE7952844A43 Q28477176-171E69A1-57E6-4DBD-97B7-11FE537E2032 Q28588904-C4C02D32-F714-419E-9CC7-3721E7082E81 Q30504401-B579EFE3-A1EB-410A-817D-AB0A87626AFE Q30577627-A8A2D352-A0D9-4E39-9D43-4AE913682DF2 Q33278139-2BC3B231-393D-420E-8DBE-9960CC7CA8CA Q33359905-EBBA0368-8C9E-45C1-8097-605FBE8D23EC Q33367858-5DFB0691-20FE-4EDF-AF98-697F08811A6B Q33368779-74EC3450-B2DC-4B03-9DC2-E268CBCB1467 Q33369765-031646AA-2FBE-4B40-B964-7D99FA056C68 Q33370540-E6BCA2E2-3F39-49CE-A167-99187EFF930D Q33371131-FADC32E4-FF16-43DD-B04D-D3F4EA079DBB Q33372115-2683E366-D82F-44E4-AA0D-AE8CA2F9CE83 Q33373608-3B75F4F8-8D04-4417-AC3E-99F11D58447B Q33374872-F3D2F74D-3CC8-43A3-AD93-DBDEAEF63357 Q33376071-4780D247-6282-4F76-A6D0-62FD17CB7406 Q33378755-10C9D5AA-3E9C-4972-B212-B0124BDE92AA Q33381813-6E8701E5-5138-4FDB-BEB7-A0A20347B2CD Q33382570-64F65FF1-2E6E-4334-AFC4-576457A47984 Q33387616-DDEFC718-4D33-4846-B884-231B8698C6F3 Q33395145-B70BD7B5-855F-4653-A6D7-76D06B33F818 Q33398887-392DDD11-6CA5-4B60-819A-B833946B7AA9 Q33399396-9C697DD7-FF25-4286-B212-0F8CC551FDED Q33400891-6ECC817C-74F2-40E6-9FA5-D936AFDAD813 Q33407332-63A698D8-C11B-4B44-BB7E-80DD47998795 Q33426377-DFD056C6-42AE-4ACC-BC0A-167A68C7DE68 Q33431193-C8D61B57-CED2-4578-AD3B-2445E9EAAA32

P2860

ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage.

http://www.wikidata.org/entity/Q33349055

description

2003 nî lūn-bûn

@nan

2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

ADAMTS-13 cysteine-rich/spacer ...... on Willebrand factor cleavage.

@ast

ADAMTS-13 cysteine-rich/spacer ...... on Willebrand factor cleavage.

@en

type

label

ADAMTS-13 cysteine-rich/spacer ...... on Willebrand factor cleavage.

@ast

ADAMTS-13 cysteine-rich/spacer ...... on Willebrand factor cleavage.

@en

prefLabel

ADAMTS-13 cysteine-rich/spacer ...... on Willebrand factor cleavage.

@ast

ADAMTS-13 cysteine-rich/spacer ...... on Willebrand factor cleavage.

@en

P1433

Q33349055-A72B83B7-9F44-44EA-AD5B-2C2DB9D3F160

P1476

Q33349055-2B251819-1DFC-49C4-A0C2-A85DC3DADFC3

P2093

Q33349055-3E18C182-6A8E-48F1-B0A5-E58E6B03B210

Q33349055-599A09EF-C7F5-4E5A-9A95-18E4E6797D5D

Q33349055-797F2E2C-12FD-4229-BF0A-3F721FC4E803

Q33349055-865077D2-25DB-4EE5-9B21-2161C0833D47

Q33349055-C218146D-C159-46A8-ADE3-FD4D5B546DEB

Q33349055-C53DE731-35B5-4CDD-B669-95E07BB8B8FD

Q33349055-C74C9A87-A531-41FB-B4BD-2E7A3BAA6E1E

Q33349055-D02AEEBA-7C9F-4B9F-89F7-6068D5E86588

Q33349055-D675C9D8-3A35-4C3D-9B21-7C16CB0A1037

Q33349055-F1332901-22AC-4653-9770-075760AA3B1B

P304

Q33349055-06DB7D8A-266D-4E13-95ED-6E4A8549C498

P31

Q33349055-A0FADDFB-0928-4B0C-AFBB-1239609FA19C

P356

Q33349055-B859BC5C-80B6-462A-8908-4D35F125066E

P407

Q33349055-9EA836C5-12C7-477F-9A63-FB8575E10DEA

P433

Q33349055-12D4AB7D-8FED-4666-BA79-F407FE26B254

P478

Q33349055-9C115962-943D-4B1F-A070-9C678DC3D8E8

P577

Q33349055-E14E54B8-E5ED-45A2-BD7E-24126248520B

P5875

Q33349055-68157B74-1F70-451D-9C95-9F972CF7C054

P698

Q33349055-72B0DCF1-7885-4369-91BE-8E990AF63C20

P356

BLOOD-2003-03-0908

P1433

P1476

ADAMTS-13 cysteine-rich/spacer ...... on Willebrand factor cleavage.

@en

P2093

Chikateru Nozaki

http://www.w3.org/2001/XMLSchema#string

Hideo Yagi

http://www.w3.org/2001/XMLSchema#string

Hiroaki Maeda

http://www.w3.org/2001/XMLSchema#string

Hiromichi Ishizashi

http://www.w3.org/2001/XMLSchema#string

Kenji Soejima

http://www.w3.org/2001/XMLSchema#string

Koichi Kokame

http://www.w3.org/2001/XMLSchema#string

Masanori Matsumoto

http://www.w3.org/2001/XMLSchema#string

Tomohiro Nakagaki

http://www.w3.org/2001/XMLSchema#string

Toshiyuki Miyata

http://www.w3.org/2001/XMLSchema#string

Yoshihiro Fujimura

http://www.w3.org/2001/XMLSchema#string

P304

3232-3237

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2003-03-0908

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P577

2003-07-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10654109

http://www.w3.org/2001/XMLSchema#string

P698

12869506

http://www.w3.org/2001/XMLSchema#string